Serous Carcinoma Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting serous carcinoma clinical trials across 8 countries. Studies span Phase 2, Phase 1, Not Applicable. Top locations include Los Angeles, California, United States, New Haven, Connecticut, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Serous Carcinoma Trials at a Glance

7 actively recruiting trials for serous carcinoma are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Los Angeles, New Haven, and Boston. Lead sponsors running serous carcinoma studies include Joyce Liu, MD, Shandong University, and Bristol-Myers Squibb.

Browse serous carcinoma trials by phase

Treatments under study

About Serous Carcinoma Clinical Trials

Looking for clinical trials for Serous Carcinoma? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Serous Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Serous Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

Non-small Cell Lung Cancer (NSCLC)High-grade Serous Ovarian Carcinoma (HGSOC)Uterine Serous Carcinoma (USC)
Bristol-Myers Squibb240 enrolled17 locationsNCT06476808
Recruiting
Phase 2

Azenosertib in Uterine Serous Carcinoma: Biomarker Study

Uterine CancerUterine Serous CarcinomaUterine Carcinoma
Joyce Liu, MD25 enrolled2 locationsNCT06369155
Recruiting
Phase 1Phase 2

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Triple-Negative Breast CancerAdvanced Solid TumorHead and Neck Squamous Cell Carcinoma+7 more
Volastra Therapeutics, Inc.200 enrolled14 locationsNCT05902988
Recruiting
Phase 2

A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

HER2/Neu+ Uterine Serous Carcinoma
Yale University50 enrolled3 locationsNCT02491099
Recruiting
Not Applicable

Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC

High Grade Serous CarcinomaHigh Grade Ovarian Serous Adenocarcinoma
Turku University Hospital200 enrolled1 locationNCT04846933
Recruiting
Phase 2

Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer

Ovarian CancerFallopian Tube CancerOvary Cancer+4 more
University College, London80 enrolled1 locationNCT05080556
Recruiting
Phase 2

Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

Endometrial CarcinomaSerous Carcinoma
Shandong University83 enrolled1 locationNCT04716686